News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Receptos Reports First Quarter 2014 Financial Results


5/12/2014 9:56:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, May 12, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT) today provided development program updates and announced financial results for the first quarter ended March 31, 2014. "We have successfully initiated the Phase 3 portion of the RADIANCE trial of RPC1063 in relapsing multiple sclerosis, with many of the Phase 2 clinical trial sites able to begin enrolling Phase 3 patients," said Faheem Hasnain, Chief Executive Officer of Receptos. "We look forward to near-term top-line results of the Phase 2 portion of RADIANCE, as well as TOUCHSTONE, our Phase 2 study of RPC1063 in ulcerative colitis, and continued progress with our pipeline programs."

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Receptos
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES